Detalhe da pesquisa
1.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
2.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919668
3.
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
Eur J Haematol
; 110(2): 177-187, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319588
4.
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Br J Haematol
; 196(4): 947-953, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34865212
5.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Haematologica
; 107(9): 2108-2120, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021599
6.
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
J Pharmacol Exp Ther
; 372(3): 331-338, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31871305
7.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol
; 94(12): 1353-1363, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512258
8.
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Future Oncol
; 12(15): 1759-68, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27093976
9.
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Clin Cancer Res
; 30(3): 498-505, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955424
10.
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Clin Cancer Res
; 29(16): 3065-3073, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314786
11.
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Blood Adv
; 7(18): 5294-5303, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315225
12.
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Cancers (Basel)
; 15(11)2023 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296940
13.
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Leuk Res
; 102: 106520, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33611131
14.
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
J Clin Oncol
; 39(6): 576-585, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026937
15.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
J Clin Oncol
; 39(34): 3853-3865, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618601
16.
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Leuk Res
; 97: 106432, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32911375
17.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Leukemia
; 34(3): 787-798, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628428
18.
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Clin Cancer Res
; 26(15): 3918-3927, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209572
19.
Does chemotherapy have a role before hormone-resistant disease develops?
Curr Urol Rep
; 10(3): 226-35, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19371481
20.
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Blood Adv
; 3(12): 1799-1807, 2019 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31196847